Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
10 nov. 2022 07h00 HE
|
Optinose, Inc.
Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023 Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE’s Current Nasal Polyps...
![Sucampo Logo](http://www.globenewswire.com/fr/Attachment/LogoDisplay/262754?filename=262754.jpg&size=2)
Sucampo and Takeda Initiate Pivotal Trial of Lubiprostone Liquid Formulation in Adults With Chronic Idiopathic Constipation
23 oct. 2013 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md. and DEERFIELD, Ill., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals...